A Study of Minirin Melt in Patients With Nocturia

This is a confirmation of safety profile for Minirin Melt in clinical practice.

Completed

Looking for future studies?

Key information

Conditions

Nocturia Lower Urinary Tract Symptoms Pathological Conditions, Signs and Symptoms Signs and Symptoms Urological Manifestations

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nemocnice Rudolfa a Stefanie, Benešov, Czechia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

nocturia

Exclusion criteria

habitual or psychogenic polydipsia
known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics
moderate and severe renal insufficiency
know hyponatremia
syndrome of inappropriate ADH secretion

Treatment and study plan

Primary outcomes

Verify the safety profile

Time frame: 12 months

Secondary outcomes

Safety aspect of dosage

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

Retrospective Safety Study in 12 Months Treatment Nocturia With Minirin Melt in Clinical Practice in Czech Republic

Important dates

Study start: 2010
Primary completion: 2013
Study completion: 2013
First posted: Sep 30, 2010
Registry last updated: Jan 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed